Faron Pharmaceuticals Oy (LSE:FARN) Share Price

Company Profile

Business description
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
Contact
Joukahaisenkatu 6 B
Turku20520
FIN
T: +358 24695151
E: [email protected]
https://www.faron.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
33

Recommended

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.

Tom Lauricella | 19 June 2026

Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.

Brian Colello, CPA | 19 June 2026

Most Australians will end up owning SpaceX — whether they like it or not.

Tyger Fitzpatrick | 19 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,045.50	27.70	-0.31%
CAC 40	8,467.98	37.19	0.44%
DAX 40	25,026.80	92.13	0.37%
Dow JONES (US)	51,564.70	72.15	0.14%
FTSE 100	10,399.70	108.91	-1.04%
HKSE	23,924.81	387.35	-1.59%
NASDAQ	26,517.93	496.28	1.91%
Nikkei 225	71,608.72	555.23	0.78%
NZX 50 Index	13,416.34	53.03	0.40%
S&P 500	7,500.58	80.48	1.08%
S&P/ASX 200	8,827.00	29.60	-0.33%
SSE Composite Index	4,090.48	17.59	-0.43%